{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T11:53:08Z","timestamp":1791287588815,"version":"4.1.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2009,11,1]],"date-time":"2009-11-01T00:00:00Z","timestamp":1257033600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,12,2]],"date-time":"2015-12-02T00:00:00Z","timestamp":1449014400000},"content-version":"vor","delay-in-days":2222,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Thoracic Oncology"],"published-print":{"date-parts":[[2009,11]]},"DOI":"10.1097\/jto.0b013e3181b62572","type":"journal-article","created":{"date-parts":[[2009,10,27]],"date-time":"2009-10-27T03:19:24Z","timestamp":1256613564000},"page":"1415-1419","source":"Crossref","is-referenced-by-count":128,"title":["Efficacy of Erlotinib for Brain and Leptomeningeal Metastases in Patients with Lung Adenocarcinoma Who Showed Initial Good Response to Gefitinib"],"prefix":"10.1016","volume":"4","author":[{"given":"Tatsuya","family":"Katayama","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junichi","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichi","family":"Suda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryoichi","family":"Onozato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Fukui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunzo","family":"Hatooka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taijiro","family":"Sueda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toyoaki","family":"Hida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasushi","family":"Yatabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuya","family":"Mitsudomi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1097\/JTO.0b013e3181b62572_bib1","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1056\/NEJMoa040938","article-title":"Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib","volume":"350","author":"Lynch","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1097\/JTO.0b013e3181b62572_bib2","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.1200\/JCO.2005.00.992","article-title":"Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence","volume":"23","author":"Mitsudomi","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e3181b62572_bib3","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1007\/s10147-006-0583-4","article-title":"Biological and clinical implications of EGFR mutations in lung cancer","volume":"11","author":"Mitsudomi","year":"2006","journal-title":"Int J Clin Oncol"},{"key":"10.1097\/JTO.0b013e3181b62572_bib4","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1126\/science.1099314","article-title":"EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy","volume":"304","author":"Paez","year":"2004","journal-title":"Science"},{"key":"10.1097\/JTO.0b013e3181b62572_bib5","doi-asserted-by":"crossref","first-page":"5764","DOI":"10.1158\/1078-0432.CCR-06-0714","article-title":"Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib","volume":"12","author":"Kosaka","year":"2006","journal-title":"Clin Cancer Res"},{"issue":"Suppl 8","key":"10.1097\/JTO.0b013e3181b62572_bib6","first-page":"LBA2","article-title":"Phase III, randomized, open-label, first-line study of gefitinib (G) vs carboplatin\/paclitaxel (C\/P) in clinically selected patients (pts) with advanced non-small-cell lung cancer (NSCLC) (IPASS)","volume":"19","author":"Mok","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1097\/JTO.0b013e3181b62572_bib7","doi-asserted-by":"crossref","first-page":"4517","DOI":"10.1200\/JCO.2006.06.6126","article-title":"Response and resistance in a non-small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinib","volume":"24","author":"Jackman","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e3181b62572_bib8","doi-asserted-by":"crossref","first-page":"e4576","DOI":"10.1371\/journal.pone.0004576","article-title":"Alterations in genes of the EGFR signaling pathway and their relationship to EGFR tyrosine kinase inhibitor sensitivity in lung cancer cell lines","volume":"4","author":"Gandhi","year":"2009","journal-title":"PLoS One"},{"key":"10.1097\/JTO.0b013e3181b62572_bib9","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1200\/JCO.20.1.110","article-title":"Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition","volume":"20","author":"Albanell","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e3181b62572_bib10","doi-asserted-by":"crossref","first-page":"3815","DOI":"10.1200\/JCO.2002.03.038","article-title":"Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial","volume":"20","author":"Herbst","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e3181b62572_bib11","doi-asserted-by":"crossref","first-page":"4292","DOI":"10.1200\/JCO.2002.03.100","article-title":"Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types","volume":"20","author":"Baselga","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e3181b62572_bib12","doi-asserted-by":"crossref","first-page":"3267","DOI":"10.1200\/JCO.2001.19.13.3267","article-title":"Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies","volume":"19","author":"Hidalgo","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e3181b62572_bib13","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1200\/JCO.2002.10.112","article-title":"ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial","volume":"20","author":"Ranson","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e3181b62572_bib14","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1097\/01.pas.0000157935.28066.35","article-title":"EGFR mutation is specific for terminal respiratory unit type adenocarcinoma","volume":"29","author":"Yatabe","year":"2005","journal-title":"Am J Surg Pathol"},{"key":"10.1097\/JTO.0b013e3181b62572_bib15","doi-asserted-by":"crossref","first-page":"e73","DOI":"10.1371\/journal.pmed.0020073","article-title":"Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain","volume":"2","author":"Pao","year":"2005","journal-title":"PLoS Med"},{"key":"10.1097\/JTO.0b013e3181b62572_bib16","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1056\/NEJMoa044238","article-title":"EGFR mutation and resistance of non-small-cell lung cancer to gefitinib","volume":"352","author":"Kobayashi","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1097\/JTO.0b013e3181b62572_bib17","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/nbt1068","article-title":"A small molecule-kinase interaction map for clinical kinase inhibitors","volume":"23","author":"Fabian","year":"2005","journal-title":"Nat Biotechnol"},{"key":"10.1097\/JTO.0b013e3181b62572_bib18","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1200\/JCO.2003.10.038","article-title":"Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]","volume":"21","author":"Fukuoka","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e3181b62572_bib19","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1001\/jama.290.16.2149","article-title":"Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial","volume":"290","author":"Kris","year":"2003","journal-title":"JAMA"},{"key":"10.1097\/JTO.0b013e3181b62572_bib20","doi-asserted-by":"crossref","first-page":"2528","DOI":"10.1200\/JCO.2006.10.4166","article-title":"Phase II study of erlotinib in advanced non-small-cell lung cancer after failure of gefitinib","volume":"25","author":"Cho","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e3181b62572_bib21","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1097\/JTO.0b013e318168c801","article-title":"Evidence for disease control with erlotinib after gefitinib failure in typical gefitinib-sensitive Asian patients with non-small cell lung cancer","volume":"3","author":"Wong","year":"2008","journal-title":"J Thorac Oncol"},{"key":"10.1097\/JTO.0b013e3181b62572_bib22","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.lungcan.2008.11.006","article-title":"Erlotinib after Gefitinib failure in female never-smoker Asian patients with pulmonary adenocarcinoma","volume":"65","author":"Sim","year":"2009","journal-title":"Lung Cancer"},{"key":"10.1097\/JTO.0b013e3181b62572_bib23","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1080\/00498250500523253","article-title":"Minimal contribution of desmethyl-gefitinib, the major human plasma metabolite of gefitinib, to epidermal growth factor receptor (EGFR)-mediated tumour growth inhibition","volume":"36","author":"McKillop","year":"2006","journal-title":"Xenobiotica"},{"key":"10.1097\/JTO.0b013e3181b62572_bib24","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1215\/15228517-2005-002","article-title":"EGFR mutations in patients with brain metastases from lung cancer: association with the efficacy of gefitinib","volume":"8","author":"Shimato","year":"2006","journal-title":"Neuro Oncol"},{"key":"10.1097\/JTO.0b013e3181b62572_bib25","doi-asserted-by":"crossref","first-page":"2525","DOI":"10.1158\/1078-0432.CCR-03-0155","article-title":"Plasma and cerebrospinal fluid pharmacokinetics of imatinib after administration to nonhuman primates","volume":"10","author":"Neville","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1097\/JTO.0b013e3181b62572_bib26","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.lungcan.2004.04.036","article-title":"Effect of gefitinib (\u2018Iressa,\u2019 ZD1839) on brain metastases in patients with advanced non-small-cell lung cancer","volume":"46","author":"Hotta","year":"2004","journal-title":"Lung Cancer"},{"key":"10.1097\/JTO.0b013e3181b62572_bib27","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.lungcan.2007.03.011","article-title":"Gefitinib as palliative therapy for lung adenocarcinoma metastatic to the brain","volume":"57","author":"Wu","year":"2007","journal-title":"Lung Cancer"},{"key":"10.1097\/JTO.0b013e3181b62572_bib28","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.lungcan.2004.05.014","article-title":"Gefitinib is active in patients with brain metastases from non-small cell lung cancer and response is related to skin toxicity","volume":"47","author":"Chiu","year":"2005","journal-title":"Lung Cancer"},{"key":"10.1097\/JTO.0b013e3181b62572_bib29","doi-asserted-by":"crossref","first-page":"3032","DOI":"10.1158\/1078-0432.CCR-04-2149","article-title":"Gefitinib as a first-line therapy of advanced or metastatic adenocarcinoma of the lung in never-smokers","volume":"11","author":"Lee","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1097\/JTO.0b013e3181b62572_bib30","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1093\/annonc\/mdh276","article-title":"Gefitinib in patients with brain metastases from non-small-cell lung cancer: a prospective trial","volume":"15","author":"Ceresoli","year":"2004","journal-title":"Ann Oncol"},{"key":"10.1097\/JTO.0b013e3181b62572_bib31","doi-asserted-by":"crossref","first-page":"123","DOI":"10.3816\/CLC.2004.n.026","article-title":"Gefitinib in patients with brain metastases from non-small-cell lung cancer: review of 15 clinical cases","volume":"6","author":"Namba","year":"2004","journal-title":"Clin Lung Cancer"},{"key":"10.1097\/JTO.0b013e3181b62572_bib32","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S1470-2045(01)00622-2","article-title":"The seed and soil hypothesis: vascularisation and brain metastases","volume":"3","author":"Fidler","year":"2002","journal-title":"Lancet Oncol"},{"key":"10.1097\/JTO.0b013e3181b62572_bib33","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.lungcan.2008.10.016","article-title":"Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are effective for leptomeningeal metastasis from non-small cell lung cancer patients with sensitive EGFR mutation or other predictive factors of good response for EGFR TKI","volume":"65","author":"Yi","year":"2009","journal-title":"Lung Cancer"}],"container-title":["Journal of Thoracic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086415312570?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086415312570?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,15]],"date-time":"2018-12-15T15:28:57Z","timestamp":1544887737000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1556086415312570"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,11]]},"references-count":33,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2009,11]]}},"alternative-id":["S1556086415312570"],"URL":"https:\/\/doi.org\/10.1097\/jto.0b013e3181b62572","relation":{},"ISSN":["1556-0864"],"issn-type":[{"value":"1556-0864","type":"print"}],"subject":[],"published":{"date-parts":[[2009,11]]}}}